ArticleAntimicrobial agents and chemotherapy2004
Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04126304 (Multi-center Investigation and Study of Mycoplasma Pneumoniae Infection and Macrolide Drug Resistance in Outpatient and In-hospital Pediatric Acute Respiratory Diseases Illness in China), which is not on this map. Cited by 120 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi-center Investigation and Study of Mycoplasma Pneumoniae Infection and Macrolide Drug Resistance in Outpatient and In-hospital Pediatric Acute Respiratory Diseases Illness in China
Who cites it
120 citing papers in PubMed, 2 syntheses or guidelines pooled it, 249 citations in OpenAlex.
- Association between point mutations of macrolide-resistantFrontiers in pharmacology · 2025Pooled it
- Guidelines for the management of adult lower respiratory tract infections--full version.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2011Guideline
- Trial
- Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients.Antimicrobial agents and chemotherapy · 2013Trial
- Epidemiological Characteristics and Clinical Impact of Macrolide-Resistant Mycoplasma pneumoniae Infection in Children in Southwest China, 2021-2025.The clinical respiratory journal · 2026Article
- Genomic Surveillance Reveals Emergence and Spread of Macrolide-Resistant Mycoplasma pneumoniae in Australia During the 2023-2024 Epidemic.The Journal of infectious diseases · 2026Article
- Detection and antimicrobial susceptibility of genital mycoplasmas in women and men, with 23S rRNA and parC mutation analysis in Mycoplasma genitalium.Scientific reports · 2026Article
- Post-pandemic surge ofJournal of clinical microbiology · 2026Article
- Article
- Clinical performance of two commercial PCR assays for the detection of macrolide resistance inJournal of clinical microbiology · 2026Article
- Role of Serum Inflammatory Biomarkers in Risk Stratification of Hospitalized Children with Macrolide-Non-ResponsiveChildren (Basel, Switzerland) · 2026Article
- Association analysis of Mycoplasma pneumoniae 23S rRNA gene mutation with refractory Mycoplasma pneumoniae pneumonia in children.PloS one · 2026Article
- Therapeutic efficacy of lascufloxacin in patients withMicrobiology spectrum · 2025Observational
- Multiplex amplicon sequencing for the comprehensive genotyping ofMicrobiology spectrum · 2025Article
- A novel azithromycin resistance mutation in Mycoplasma genitalium induced in vitro.The Journal of antimicrobial chemotherapy · 2025Article
- Whole-genome probe capture sequencing reveals genomic diversity and characteristics ofFrontiers in microbiology · 2025Article
- Proteomics profiling of serum exosomes from azithromycin-sensitive and resistantFrontiers in medicine · 2025Article
- Antimicrobial susceptibility and molecular characteristics ofFrontiers in pediatrics · 2025Article
- Macrolide resistance inFrontiers in cellular and infection microbiology · 2025Article
- New-generation tetracyclines for severe macrolide-resistant Mycoplasma pneumoniae pneumonia in children: a retrospective analysis.BMC infectious diseases · 2024Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, Mycoplasma pneumoniae strains that are clinically resistant to macrolide antibiotics have occasionally been encountered in Japan. Of 76 strains of M. pneumoniae isolated in three different areas in Japan during 2000 to 2003, 13 strains were erythromycin (ERY) resistant. Of these 13 strains, 12 were highly ERY resistant (MIC, > or =256 microg/ml) and 1 was weakly resistant (MIC, 8 microg/ml). Nucleotide sequencing of domains II and V of 23S rRNA and ribosomal proteins L4 and L22, which are associated with ERY resistance, showed that 10 strains had an A-to-G transition at position 2063 (corresponding to 2058 in Escherichia coli numbering), 1 strain showed A-to-C transversion at position 2063, 1 strain showed an A-to-G transition at position 2064, and the weakly ERY-resistant strain showed C-to-G transversion at position 2617 (corresponding to 2611 in E. coli numbering) of domain V. Domain II and ribosomal proteins L4 and L22 were not involved in the ERY resistance of these clinical M. pneumoniae strains. In addition, by using our established restriction fragment length polymorphism technique to detect point mutations of PCR products for domain V of the 23S rRNA gene of M. pneumoniae, we found that 23 (24%) of 94 PCR-positive oral samples taken from children with respiratory infections showed A2063G mutation. These results suggest that ERY-resistant M. pneumoniae infection is not unusual in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.